|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00512 GRAND PHARMA
Nominal 
4.750 0.000 (0.000%) | 2024/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | |
| Turnover | 6,047,236 | 0.964% | 10,529,590 | 9,562,285 | 8,597,975 | 6,352,919 |
| Cost of Sales | (2,455,927) | 15.788% | (4,005,524) | (3,610,806) | (3,350,737) | (2,317,725) |
| Gross Profit | 3,591,309 | -7.164% | 6,524,066 | 5,951,479 | 5,247,238 | 4,035,194 |
| 2024/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 443,749 | 161.020% | 18,763 | (91,345) | (8,350) | 253,604 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (58,664) | 23,017 | 484,495 | -- | |
| Share of Results of Asso. & JCEs | 18,816 | -- | (25,008) | (43,786) | 113,862 | 61,979 | |
| Profit / (Loss) before Taxation | 1,831,882 | 38.183% | 2,344,197 | 2,516,893 | 2,785,832 | 2,073,583 | |
| Taxation | (244,175) | -9.204% | (448,755) | (418,642) | (380,800) | (292,374) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (29,762) | 8.553% | (15,444) | (18,832) | (2,469) | 11,452 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,557,945 | 51.352% | 1,879,998 | 2,079,419 | 2,402,563 | 1,792,661 | |
| 2024/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | |
| Net Finance Costs / (Income) | 86,121 | -23.944% | 197,400 | 117,687 | 18,011 | 97,375 |
| Depreciation & Amortisation | 249,159 | 30.072% | 392,210 | 394,912 | 339,519 | 287,061 |
| Directors' Emoluments | -- | -- | 8,988 | 6,357 | 4,554 | 2,434 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 44.410 | 52.507% | 53.600 | 58.700 | 67.720 | 52.030 |
| DPS (cts) | 0.000 | -- | 26.000 | 14.000 | 11.000 | 11.000 |
| Dividend Payout Ratio (%) | -- | -- | 48.507% | 23.850% | 16.243% | 21.142% |
| Cash flow per share ($) | -- | -- | 0.691 | 0.520 | 0.565 | 0.423 |
| NBV per share ($) | 4.428 | -- | 4.270 | 3.984 | 3.773 | 3.166 |
| Remarks: | Real time quote last updated: 27/12/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 1,557,945 |
| %Change | 51.352% |
| EPS / (LPS) | HKD 0.444 |
| NBV Per Share ($) | HKD 4.428 |